Differential effects of denileukin diftitox IL-2 immunotoxin on NK and regulatory T cells in nonhuman primates

Journal of Immunology

Volumn 188, Issue 12, 2012, Pages 6063-6070

  Yamada, Yohei ^a   Aoyama, Akihiro ^a   Tocco, Georges ^a   Boskovic, Svjetlan ^a   Nadazdin, Ognjenka ^a   Alessandrini, Alessandro ^a   Madsen, Joren C ^a   Cosimi, A Benedict ^a   Benichou, Gilles ^a   Kawai, Tatsuo ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD45RA ANTIGEN; DENILEUKIN DIFTITOX; INTERLEUKIN 15; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER PATIENT; CELL SURVIVAL; CONCENTRATION RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG POTENCY; IMMUNOTOXICITY; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LOW DRUG DOSE; LYMPHOCYTE COUNT; MACACA FASCICULARIS; MALE; MULTIPLE DRUG DOSE; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

ANIMALS; ANTINEOPLASTIC AGENTS; DIPHTHERIA TOXIN; FLOW CYTOMETRY; IMMUNOTOXINS; INTERLEUKIN-15; INTERLEUKIN-2; KILLER CELLS, NATURAL; MACACA FASCICULARIS; MALE; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, REGULATORY;

EID: 84862591399     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1200656     Document Type: Article

References (44)

1. Morse, M. A., A. C. Hobeika, T. Osada, D. Serra, D. Niedzwiecki, H. K. Lyerly, and T. M. Clay. 2008. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 112: 610-618.
2. Litzinger, M. T., R. Fernando, T. J. Curiel, D. W. Grosenbach, J. Schlom, and C. Palena. 2007. IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood 110: 3192-3201. (Pubitemid 350106311)
3. Dannull, J., S. Nair, Z. Su, D. Boczkowski, C. DeBeck, B. Yang, E. Gilboa, and J. Vieweg. 2005. Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand. Blood 105: 3206-3213.
4. Mahnke, K., K. Schönfeld, S. Fondel, S. Ring, S. Karakhanova, K. Wiedemeyer, T. Bedke, T. S. Johnson, V. Storn, S. Schallenberg, and A. H. Enk. 2007. Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int. J. Cancer 120: 2723-2733. (Pubitemid 46651297)
5. Salagianni, M., E. Lekka, A. Moustaki, E. G. Iliopoulou, C. N. Baxevanis, M. Papamichail, and S. A. Perez. 2011. NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses. J. Immunol. 186: 3327-3335.
6. Dannull, J., Z. Su, D. Rizzieri, B. K. Yang, D. Coleman, D. Yancey, A. Zhang, P. Dahm, N. Chao, E. Gilboa, and J. Vieweg. 2005. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 115: 3623-3633. (Pubitemid 43121851)
7. Rasku, M. A., A. L. Clem, S. Telang, B. Taft, K. Gettings, H. Gragg, D. Cramer, S. C. Lear, K. M. McMasters, D. M. Miller, and J. Chesney. 2008. Transient T cell depletion causes regression of melanoma metastases. J. Transl. Med. 6: 12.
8. Foss, F. 2006. Clinical experience with denileukin diftitox (ONTAK). Semin. Oncol. 33(1, Suppl. 3)S11-S16.
9. Gerena-Lewis, M., J. Crawford, P. Bonomi, A. M. Maddox, J. Hainsworth, D. E. McCune, R. Shukla, H. Zeigler, P. Hurtubise, T. R. Chowdhury, et al. 2009. A Phase II trial of Denileukin Diftitox in patients with previously treated advanced non-small cell lung cancer. Am. J. Clin. Oncol. 32: 269-273.
10. Ferrara, J. L. 2007. Novel strategies for the treatment and diagnosis of graftversus- host-disease. Best Pract. Res. Clin. Haematol. 20: 91-97.
11. Talpur, R., N. Apisarnthanarax, S. Ward, and M. Duvic. 2002. Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK). Leuk. Lymphoma 43: 121-126. (Pubitemid 34223979)
12. Dang, N. H., L. Fayad, P. McLaughlin, J. E. Romaguara, F. Hagemeister, A. Goy, S. Neelapu, F. Samaniego, P. L. Walker, M. Wang, et al. 2007. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory Bcell non-Hodgkin lymphoma. Br. J. Haematol. 138: 502-505. (Pubitemid 47063035)
13. Dang, N. H., F. B. Hagemeister, B. Pro, P. McLaughlin, J. E. Romaguera, D. Jones, B. Samuels, F. Samaniego, A. Younes, M. Wang, et al. 2004. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. J. Clin. Oncol. 22: 4095-4102. (Pubitemid 41185178)
14. Attia, P., A. V. Maker, L. R. Haworth, L. Rogers-Freezer, and S. A. Rosenberg. 2005. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J. Immunother. 28: 582-592. (Pubitemid 41533092)
15. Barnett, B., I. Kryczek, P. Cheng, W. Zou, and T. J. Curiel. 2005. Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am. J. Reprod. Immunol. 54: 369-377. (Pubitemid 41748714)
16. Knutson, K. L., Y. Dang, H. Lu, J. Lukas, B. Almand, E. Gad, E. Azeke, and M. L. Disis. 2006. IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J. Immunol. 177: 84-91. (Pubitemid 43939119)
17. Kiyokawa, T., D. P. Williams, C. E. Snider, T. B. Strom, and J. R. Murphy. 1991. Protein engineering of diphtheria-toxin-related interleukin-2 fusion toxins to increase cytotoxic potency for high-affinity IL-2-receptor-bearing target cells. Protein Eng. 4: 463-468.
18. Re, G. G., C. Waters, L. Poisson, M. C. Willingham, K. Sugamura, and A. E. Frankel. 1996. Interleukin 2 (IL-2) receptor expression and sensitivity to diphteria fusion toxin DAB389IL-2 in cultured hematopoietic cells. Cancer Res. 56: 2590-2595.
19. Foss, F. M. 2001. Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma. Ann. N. Y. Acad. Sci. 941: 166-176. (Pubitemid 32928343)
20. Mavilio, D., J. Benjamin, D. Kim, G. Lombardo, M. Daucher, A. Kinter, E. Nies- Kraske, E. Marcenaro, A. Moretta, and A. S. Fauci. 2005. Identification of NKG2A and NKp80 as specific natural killer cell markers in rhesus and pigtailed monkeys. Blood 106: 1718-1725. (Pubitemid 41208586)
21. Miyara, M., Y. Yoshioka, A. Kitoh, T. Shima, K. Wing, A. Niwa, C. Parizot, C. Taflin, T. Heike, D. Valeyre, et al. 2009. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30: 899-911.
22. Meazza, R., B. Azzarone, A. M. Orengo, and S. Ferrini. 2011. Role of common-gamma chain cytokines in NK cell development and function: perspectives for immunotherapy. J. Biomed. Biotechnol. 2011: 861920.
23. Moustaki, A., K. V. Argyropoulos, C. N. Baxevanis, M. Papamichail, and S. A. Perez. 2011. Effect of the simultaneous administration of glucocorticoids and IL-15 on human NK cell phenotype, proliferation and function. Cancer Immunol. Immunother. 60: 1683-1695.
24. Jakobisiak, M., J. Golab, and W. Lasek. 2011. Interleukin 15 as a promising candidate for tumor immunotherapy. Cytokine Growth Factor Rev. 22: 99-108.
25. Giri, J. G., S. Kumaki, M. Ahdieh, D. J. Friend, A. Loomis, K. Shanebeck, R. DuBose, D. Cosman, L. S. Park, and D. M. Anderson. 1995. Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor. EMBO J. 14: 3654-3663.
26. Giri, J. G., D. M. Anderson, S. Kumaki, L. S. Park, K. H. Grabstein, and D. Cosman. 1995. IL-15, a novel T cell growth factor that shares activities and receptor components with IL-2. J. Leukoc. Biol. 57: 763-766.
27. Giri, J. G., M. Ahdieh, J. Eisenman, K. Shanebeck, K. Grabstein, S. Kumaki, A. Namen, L. S. Park, D. Cosman, and D. Anderson. 1994. Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J. 13: 2822-2830. (Pubitemid 24191692)
28. Lugli, E., C. K. Goldman, L. P. Perera, J. Smedley, R. Pung, J. L. Yovandich, S. P. Creekmore, T. A. Waldmann, and M. Roederer. 2010. Transient and persistent effects of IL-15 on lymphocyte homeostasis in nonhuman primates. Blood 116: 3238-3248.
29. Walz, G., B. Zanker, K. Brand, C.Waters, F. Genbauffe, J. B. Zeldis, J. R. Murphy, and T. B. Strom. 1989. Sequential effects of interleukin 2-diphtheria toxin fusion protein on T-cell activation. Proc. Natl. Acad. Sci. USA 86: 9485-9488. (Pubitemid 20010451)
30. Zorn, E., E. A. Nelson, M. Mohseni, F. Porcheray, H. Kim, D. Litsa, R. Bellucci, E. Raderschall, C. Canning, R. J. Soiffer, et al. 2006. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 108: 1571-1579. (Pubitemid 44316124)
31. Shields, L. E., A. J. Sieverkropp, J. Potter, and R. G. Andrews. 2006. Phenotypic and cytolytic activity of Macaca nemestrina natural killer cells isolated from blood and expanded in vitro. Am. J. Primatol. 68: 753-764. (Pubitemid 44266154)
32. Webster, R. L., and R. P. Johnson. 2005. Delineation of multiple subpopulations of natural killer cells in rhesus macaques. Immunology 115: 206-214. (Pubitemid 40733406)
33. Vargas-Inchaustegui, D. A., T. Demberg, and M. Robert-Guroff. 2011. A CD8a (2) subpopulation of macaque circulatory natural killer cells can mediate both antibody-dependent and antibody-independent cytotoxic activities. Immunology 134: 326-340.
34. Malek, T. R. 2008. The biology of interleukin-2. Annu. Rev. Immunol. 26: 453-479. (Pubitemid 351600382)
35. Waters, C. A., P. A. Schimke, C. E. Snider, K. Itoh, K. A. Smith, J. C. Nichols, T. B. Strom, and J. R. Murphy. 1990. Interleukin 2 receptor-targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin-related interleukin 2 fusion protein into cells. Eur. J. Immunol. 20: 785-791. (Pubitemid 20167033)
36. Foss, F. M. 2000. DAB(389)IL-2 (denileukin diftitox, ONTAK): a new fusion protein technology. Clin. Lymphoma 1(Suppl. 1): S27-S31.
37. Epardaud, M., K. G. Elpek, M. P. Rubinstein, A. R. Yonekura, A. Bellemare- Pelletier, R. Bronson, J. A. Hamerman, A. W. Goldrath, and S. J. Turley. 2008. Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. Cancer Res. 68: 2972-2983. (Pubitemid 351556298)
38. Tsunobuchi, H., H. Nishimura, F. Goshima, T. Daikoku, H. Suzuki, I. Nakashima, Y. Nishiyama, and Y. Yoshikai. 2000. A protective role of interleukin-15 in a mouse model for systemic infection with herpes simplex virus. Virology 275: 57-66.
39. Chapoval, A. I., J. A. Fuller, S. G. Kremlev, S. J. Kamdar, and R. Evans. 1998. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells. J. Immunol. 161: 6977-6984. (Pubitemid 28562246)
40. Stoklasek, T. A., K. S. Schluns, and L. Lefrançois. 2006. Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. J. Immunol. 177: 6072-6080. (Pubitemid 44628822)
41. Rubinstein, M. P., A. N. Kadima, M. L. Salem, C. L. Nguyen, W. E. Gillanders, and D. J. Cole. 2002. Systemic administration of IL-15 augments the antigen-specific primary CD8+ T cell response following vaccination with peptide-pulsed dendritic cells. J. Immunol. 169: 4928-4935. (Pubitemid 35217158)
42. Oh, S., L. P. Perera, D. S. Burke, T. A. Waldmann, and J. A. Berzofsky. 2004. IL-15/IL-15Ralpha-mediated avidity maturation of memory CD8+ T cells. Proc. Natl. Acad. Sci. USA 101: 15154-15159. (Pubitemid 39391734)
43. Berger, C., M. Berger, R. C. Hackman, M. Gough, C. Elliott, M. C. Jensen, and S. R. Riddell. 2009. Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood 114: 2417-2426.
44. Waldmann, T. A., E. Lugli, M. Roederer, L. P. Perera, J. V. Smedley, R. P. Macallister, C. K. Goldman, B. R. Bryant, J. M. Decker, T. A. Fleisher, et al. 2011. Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood 117: 4787-4795.